| ¿µ¹® | intermittent positive pressure breathing(IPPB) | ÇÑ±Û | °£ÇæÀû¾ç¾ÐÈ£Èí |
|---|---|---|---|
| ¼³¸í | Æó¸¦ ÆØÃ¢½Ã۱â À§ÇÏ¿© ´ë±â¾Ðº¸´Ù ³ôÀº ¾Ð·ÂÀ» ÀÌ¿ëÇÏ´Â ÀΰøÈ£Èí¹ýÀÌ´Ù. ½Å»ý¾Æ ¹«±âÆóÀÇ Ä¡·á³ª ¸¸¼º Æó¼â¼º È£Èí±â ÁúȯÀÇ ±Þ¼º ¾ÇȽÃ, Áø´ÜÀ» À§ÇÑ °¡·¡ÀÇ ¹èÃâÀ» À§ÇÏ¿©, ¶Ç´Â ¾àÁ¦ÀÇ ÈíÀÔ¿¡ »ç¿ëÇϰí ÀÖ´Ù. ÇÕº´ÁõÀ¸·Î °ø±â°¡½¿ÁõÀ̳ª ½É¹ÚÃâ·®ÀÇ °¨¼Ò°¡ ¿Ã ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | placebo | ÇÑ±Û | ¼ÓÀÓ¾à, ¹«È¿¾à |
|---|---|---|---|
| ¼³¸í | ¿ø·¡ ¾à¹°Åõ¿©ÀÇ ¾Ï½ÃÀû È¿°ú¸¸À¸·Î ¾à¸®ÀÛ¿ëÀ» ³ªÅ¸³»Áö ¾Ê´Â °Í. ¼ÓÀÓ¾àÀ» Åõ¿©ÇÔ¿¡ µû¶ó ³ªÅ¸³ª´Â È¿°ú¸¦ ¼ÓÀÓ¾àÈ¿°ú¶ó°í Çϸç, ¾Ï½Ã¸¦ À¯¹ßÇÏ´Â ÈûÀÌ °ÇÒ¼ö·Ï ±× È¿°ú°¡ ³ô´Ù. ¿¹¸¦ µé¾î °í°¡Á¦Ç°, ÀÔ¼öÇϱ⠾î·Á¿î Á¦Ç°, ¿Ü±¹ Á¦Ç° µîÀÌ ÀÌ¿¡ ÇØ´çÇϸç, ĸ½¶¿¡ µé¾î°£ ¾à¹°Àº Á¤Á¦º¸´Ùµµ ¼ÓÀÓ¾àÈ¿°ú°¡ ³ô´Ù. ÇÑÆí ¹Ý´ëÀÎ ¸¶À̳ʽº ¼ÓÀÓ¾àÈ¿°úµµ ÀÖ¾î, º»·¡´Â ¾ø¾úÀ» ºÎÀÛ¿ëÀ» º¸ÀÌ´Â Àϵµ ÀÖ´Ù. ½ÇÁ¦·Î´Â »ý¸® ÀÛ¿ëÀÌ ¾ø´Â ¹°Áú·Î ¸¸µç ¾àÀ¸·Î Á¥´ç-³ì¸»-¿ìÀ¯ µûÀ§¸¦ ÀÌ¿ëÇϸç, ¾î¶² ¾à¹°ÀÇ È¿°ú¸¦ ½ÃÇèÇϰųª ȯÀÚ¸¦ ÀϽÃÀûÀ¸·Î ¾È½É½Ã۱â À§ÇÏ¿© Åõ¿©ÇÑ´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| AER | abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en... |
| SR | sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat... |
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| RR | radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati... |
| DBPCFC | Double-blind placebo-controlled food challenge |
|---|---|
| P | Placebo |
| PL | Placebo |
| PLA | Placebo |
| PLAC | Placebo |
| active placebo | <pharmacology> Any dummy medical treatment, originally, a medicinal preparation having no specific pharmacological activity against the patients illness or complaint given solely for the psychophysiological effects of the treatment, more recently, a dummy treatment administered to the control group in a controlled clinical trial in order that the specific and non-specific effects of the experimental treatment can be distinguished i.e., the experimental treatment must produce better results than the placebo in order to be considered effective. (18 Nov 1997) |
|---|---|
| placebo | <pharmacology> Any dummy medical treatment, originally, a medicinal preparation having no specific pharmacological activity against the patients illness or complaint given solely for the psychophysiological effects of the treatment, more recently, a dummy treatment administered to the control group in a controlled clinical trial in order that the specific and non-specific effects of the experimental treatment can be distinguished i.e., the experimental treatment must produce better results than the placebo in order to be considered effective. (18 Nov 1997) |
| placebo effect | An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion. (12 Dec 1998) |
| CD4-positive T-lymphocytes | A critical subpopulation of regulatory T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the t4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes, which includes both the helper-inducer (T-lymphocytes, helper-inducer) and suppressor-inducer (T-lymphocytes, suppressor-inducer) T-cells. (12 Dec 1998) |
| CD8-positive T-lymphocytes | A critical subpopulation of regulatory T-lymphocytes involved in MHC class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-lymphocytes, cytotoxic) and suppressor T-lymphocytes (T-lymphocytes, suppressor-effector). (12 Dec 1998) |
| gram-positive | <microbiology> Bacteria that retain the stain or that are resistant to decolourisation by alcohol during Gram's method of staining. This is a primary characteristic of bacteria whose cell wall is composed of a thick layer of peptidologlycan containing teichoic and lipoteichoic acid complexed to the peptidoglycan. See: gram-negative (06 Oct 1997) |
| gram-positive asporogenous rods | <microbiology> A gram-positive, non-spore-forming group of bacteria comprising organisms that have morphological and physiological characteristics in common. (12 Dec 1998) |
| gram-positive asporogenous rods, irregular | <microbiology> A group of irregular rod-shaped bacteria that stain gram-positive and do not produce endospores. (12 Dec 1998) |
| gram-positive asporogenous rods, regular | <microbiology> A group of regular rod-shaped bacteria that stain gram-positive and do not produce endospores. (12 Dec 1998) |
| gram-positive bacteria | <microbiology> Bacteria which retain the crystal violet stain when treated by gram's method. (12 Dec 1998) |
| gram-positive bacterial infections | <microbiology> Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. (12 Dec 1998) |
| gram-positive cocci | <microbiology> Coccus-shaped bacteria that retain the crystal violet stain when treated by gram's method. (12 Dec 1998) |
| gram-positive endospore-forming bacteria | <microbiology> Bacteria that form endospores and are gram-positive. Representative genera include bacillus, clostridium, micromonospora, saccharopolyspora, and streptomyces. (12 Dec 1998) |
| gram-positive endospore-forming rods | <microbiology> Rod-shaped bacteria that form endospores and are gram-positive. Representative genera include bacillus and clostridium. (12 Dec 1998) |
| gram-positive rods | <microbiology> A large group of rod-shaped bacteria that retains the crystal violet stain when treated by gram's method. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|